Novo Nordisk will acquire the license of an experimental medicine against the obesity of Lexicon Pharmaceuticals in an agreement for 1,000 million dollars, the second of the Danish pharmaceutics this week, with which he intends to strengthen his portfolio of treatments to lose weight.
According to the terms of the agreement announced by Lexicon this Friday, Novo will obtain world rights to develop, manufacture and market the LX9851 drug, against obesity and associated metabolic disorders.
Novo has tried to strengthen its position in the obesity drug market, which has a potential of 150,000 million dollars, through the development of new generation drugs, acquisitions and associations.
On Monday, Novo acquired the world rights of the drug candidate for the weight loss of United International Laboratories, based in China, in an agreement worth up to 2,000 million dollars.
Lexicon has the right to receive payments in advance and for short -term milestones of up to 75 million dollars. In total, Lexicon could receive 1,000 million dollars in advances in advance and possible development, regulatory and sales milestones.
You may be interested: The Trump administration attack on RNM vaccines threatens the mastery of US biotechnology
Lexicon is testing the drug not based on incredine as independent therapy
The experimental oral drug is aimed at a protein called ACSL5 that helps to regulate fat accumulation and energy balance.
Lexicon is testing the drug not based on incredine as independent therapy and combination with LPG-1 drugs such as Novo’s semagglutide, Wegovy’s active substance, its popular weight loss treatment.
According to Yasmeen Rahimi, an analyst at Piper Sandler, the license agreement reflects Lexicon’s thoughtful approach towards the optimization of his portfolio of differentiated products and “it is a great opportunity to generate more value.”
In November, Lexicon said he planned to focus on the development of his drug candidates for conditions such as obesity and nerve damage caused by diabetes, and who was looking for partners who helped him make progress, after his drug for diabetes suffered multiple setbacks.
The company also announced that it would reduce its workforce by 60%, after the United States Food and Medicines Administration detected deficiencies in its application for the approval of Sotagliflozina, its drug for diabetes.
With Reuters information.
Follow us on Google News to always keep you informed
